Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2017

Open Access 01-12-2017 | Study protocol

Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial

Authors: Xinxing Lai, Kegang Cao, Lingbo Kong, Qiang Liu, Ying Gao, for the XMAS study investigators

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

Xingnaojing injection (XNJ) is widely used for the treatment of stroke in China. However, there is currently a lack of high-quality evidence of its efficacy for acute ischemic stroke. The main objective of this study is to determine whether the addition of XNJ to standard care improves the 3-month functional outcome in patients with acute ischemic stroke (AIS).

Methods/design

The XMAS study is a multicenter, prospective, randomized controlled, open-label trial with a blinded endpoints design. A total of 720 patients will be randomly allocated to either the intervention or the control group in a 1:1 ratio. The intervention group receives XNJ combined with standard care, and the control group receives standard care alone. XNJ will be administered intravenously every 12 h for 10 days. The primary outcome is the proportion of patients who are independent at 3 months after stroke onset defined as a modified Rankin Scale score of 0 to 2. Secondary outcomes include early neurological deterioration at 48 h, the change in National Institutes of Health Stroke Scale score, patient-reported outcome, symptomatic intracranial hemorrhage at 10 days, the Barthel Index score, deaths from any cause and cardiovascular events at 3 months.

Discussion

The results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment.

Trial registration

Clinical Trials.gov, ID: NCT02728180. Registered on 28 March 2016.
Appendix
Available only for authorised users
Literature
1.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef
2.
Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1(5):e259–81.CrossRefPubMedPubMedCentral
3.
Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence and mortality of stroke in China: results from a nationwide population-based survey of 480,687 adults. Circulation. 2017;135(8):759-71.
4.
Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–35.CrossRefPubMed
5.
6.
Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, Fang Y. Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke. 2007;38(6):1973–9.CrossRefPubMed
7.
Yu L, Wang N, Zhang Y, Wang Y, Li J, Wu Q, Liu Y. Neuroprotective effect of muscone on glutamate-induced apoptosis in PC12 cells via antioxidant and Ca2+ antagonism. Neurochem Int. 2014;70:10–21.CrossRefPubMed
8.
Wei G, Huang Y, Li F, Zeng F, Li Y, Deng R, et al. XingNaoJing, prescription of traditional Chinese medicine, prevents autophagy in experimental stroke by repressing p53-DRAM pathway. BMC Complement Altern Med. 2015;15:377.CrossRefPubMedPubMedCentral
9.
Wei J, Yao L, Yang L, Zhao W, Shi S, Cai Q, et al. Alteration of glutamate/GABA balance during acute alcohol intoxication in rats: effect of Xingnaojing injection. J Ethnopharmacol. 2015;166:333–9.CrossRefPubMed
10.
Xia X, Li Q, Liu M. Neuroprotective effect of a formula, Moschus combined with Borneolum Synthcticum, from Traditional Chinese Medicine on ischemia stroke in rats. Evid Based Complement Alternat Med. 2014;2014:1–10.
11.
Peng W, Yang J, Wang Y, Wang W, Xu J, Wang L, Xing Z. Systematic review and meta-analysis of randomized controlled trials of Xingnaojing treatment for stroke. Evid Based Complement Alternat Med. 2014;2014:210851.PubMedPubMedCentral
12.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–7.CrossRefPubMed
13.
Brott T, Adams HJ, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864–70.CrossRefPubMed
14.
Wang X, Liu Q, Zhong H, Gao Y. Second run clinical verification of patient-reported outcome scale of stroke. Chin J Tradit Chin Med Pharm. 2012;27(05):1245–8 [Article in Chinese].
15.
Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–5.PubMed
16.
Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63.CrossRefPubMed
17.
Gu C, Fu Y, Wang Y, Wu J. Xinnaojing injection in the treatment of acute ischemic stroke: a clinical trial of 85 patients. J Emerg Tradit Chin Med. 2009;18(12):1989–90 [Article in Chinese].
18.
Lian Q, Dong H, 03. Clinical observation of Xinnaojing injection in the treatment of acute ischemic stroke. J Emerg Tradit Chin Med. 2010;19:430–1 [Article in Chinese].
19.
Li M. Clinical efficacy of Xingnaojing injection in the treatment of acute ischemic stroke. Strait Pharm J. 2011;3(07):153–5 [Article in Chinese].
20.
Su S, Lu A, Li S, Jia W. Evidence-based ZHENG: a traditional Chinese medicine syndrome 2013. Evid Based Complement Alternat Med. 2014;2014:1–2.
21.
Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–60.CrossRefPubMedPubMedCentral
22.
Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003;21(7):1291–8.CrossRefPubMed
23.
O’Neil WM, Welner SA, Lip GY. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? Thromb Haemost. 2013;109(3):497–503.CrossRefPubMed
24.
Westendorp WF, Vermeij J, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJLW, et al. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015;385(9977):1519–26.CrossRefPubMed
Metadata
Title
Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial
Authors
Xinxing Lai
Kegang Cao
Lingbo Kong
Qiang Liu
Ying Gao
for the XMAS study investigators
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-2222-y

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue

Study protocol

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

Study protocol

Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey

Study protocol

Effects of action observation therapy and mirror therapy after stroke on rehabilitation outcomes and neural mechanisms by MEG: study protocol for a randomized controlled trial

Study protocol

Creation of a core outcome set for clinical trials of people with shoulder pain: a study protocol

Study protocol

Randomized trial of acupressure to improve patient satisfaction and quality of recovery in hospitalized patients: study protocol for a randomized controlled trial

Commentary

Benefits and challenges of using the cohort multiple randomised controlled trial design for testing an intervention for depression